Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.43 |
| ▸ | CES1 | P23141 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL11008818 | 0.97 | TSHR (0.53) | TSHRTHRBALDH1A1LMNAMEN1 | |
| Hexane SCHEMBL120684 | 0.96 | TSHR (0.50) | TSHRTHRBALDH1A1LMNAMEN1 | |
| Hexane SCHEMBL27710370 | 0.93 | TSHR (0.47) | TSHRTHRBALDH1A1LMNAMEN1 | |
| Hexane SCHEMBL15007841 | 0.93 | TSHR (0.47) | TSHRTHRBALDH1A1LMNAMEN1 | |
| Chloroform SCHEMBL28294775 | 0.93 | TSHR (0.67) | TSHRTHRBALDH1A1LMNAMEN1 | |
| Hexadecane SCHEMBL2833679 | 0.93 | TSHR (0.67) | TSHRTHRBALDH1A1LMNAMEN1 | |
| Octane SCHEMBL4077297 | 0.93 | TSHR (0.67) | TSHRTHRBALDH1A1LMNAMEN1 | |
| Heptane SCHEMBL349511 | 0.93 | TSHR (0.67) | TSHRTHRBALDH1A1LMNAMEN1 | |
| Heptane SCHEMBL7599758 | 0.90 | LMNA (0.56) | TSHRTHRBALDH1A1LMNAMEN1 | |
| Heptane SCHEMBL11026529 | 0.89 | TSHR (0.61) | TSHRTHRBALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10709727-B2 | Antiviral drugs | IDAC THERANOSTICS, INC. (JP) | 2020-07-14 | — | — | US | disclosed |
| US-20190022126-A1 | ANTIVIRAL DRUGS | IDAC THERANOSTICS, INC. (JP) | 2019-01-24 | — | — | US | disclosed |
| EP-3395363-A1 | ANTIVIRAL DRUG | IDAC Theranostics, Inc. (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-20130059361-A1 | Compositions and Methods for Effecting the Levels of High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein AI, Very Low Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2013-03-07 | — | — | US | disclosed |
| US-8343494-B2 | Antibodies against LLG polypeptides of the triacylglycerol lipase family | AVENTIS PHARMACEUTICALS INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120114660-A1 | Antibodies Against LLG Polypeptides of the Triacylglycerol Lipase Family | AVENTIS PHARMACEUTICALS INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120079626-A1 | LIPASE POLYPEPTIDE | UNIVERSITY OF YORK (GB) | 2012-03-29 | — | — | US | disclosed |
| US-8093452-B2 | Transgenic cell comprising vector expressing patatin; for use as tool in identifying modulators of plant growth | UNIVERSITY OF YORK (GB) | 2012-01-10 | — | — | US | disclosed |
| US-7579447-B2 | Antibodies against LLG polypeptides of the triacylglycerol lipase family | AVENTIS PHARMACEUTICALS INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090208479-A1 | Compositions and Methods for Effecting the Levels of High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein AI, Very Low Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2009-08-20 | — | — | US | disclosed |
| WO-1996017054-A1 | METHOD AND COMPOSITIONS FOR REDUCING CHOLESTEROL ABSORPTION | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1996-06-06 | — | — | WO | disclosed |
| US-5441960-A | 1-pyrimidinylacetamide human leukocyte elastate inhibitors | ZENECA LIMITED (GB) | 1995-08-15 | — | — | US | disclosed |
| US-5411956-A | Polylysine | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1995-05-02 | — | — | US | disclosed |
| EP-0636141-A1 | PYRIMIDINYL ACETAMIDES AS ELASTASE INHIBITORS. | ZENECA LTD (GB) | 1995-02-01 | — | — | EP | disclosed |
| US-5376640-A | Administering purithionin or polylysine | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-12-27 | — | — | US | disclosed |
| US-5270334-A | 4-methoxy-5-methyl-pyran-3-ol natural products and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1993-12-14 | — | — | US | disclosed |
| WO-1993021210-A1 | PYRIMIDINYL ACETAMIDES AS ELASTASE INHIBITORS | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| US-5248790-A | Antibiotics | E. R. SQUIBB & SONS, INC. (US) | 1993-09-28 | — | — | US | disclosed |
| US-4745202-A | BACTERICIDES | E. R. SQUIBB & SONS, INC. (US) | 1988-05-17 | — | — | US | disclosed |
| US-4503218-A | BACTERICIDE | E. R. SQUIBB & SONS, INC. (US) | 1985-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114660-A1 | Antibodies Against LLG Polypeptides of the Triacylglycerol Lipase Family | LIPG, LPL, LIPC | TSHR 544/4885THRB 1067/4885ALDH1A1 3758/4885 |
| US-10709727-B2 | Antiviral drugs | DOCK2, DOCK11, HAVCR2 | TSHR 4774/4885THRB 4335/4885ALDH1A1 2649/4885 |
| US-20190022126-A1 | ANTIVIRAL DRUGS | DOCK2, DOCK11, HAVCR2 | TSHR 4774/4885THRB 4335/4885ALDH1A1 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.